For someone who does not have HIV, prevention can mean a task that must be completed every day: taking medication on time. Work, travel, and changes in daily life can interrupt that routine. Privacy concerns and fear of stigma may also delay a person’s decision to begin. Effective preventive medicines already exist. Ensuring that people can keep using them is another challenge. [1]
Replacing a daily pill with treatment every six months could make prevention easier to fit into life. If the drug’s price also falls to a level at which public-health programs can consider large-scale procurement, that change may reach more people.
On November 2, 2026, the Clinton Health Access Initiative (CHAI) and its partners announced that Indian pharmaceutical company Dr. Reddy’s generic version of lenacapavir had received tentative approval from the U.S. FDA. Under an earlier agreement, the injectable drug’s price for the 120 countries covered by the voluntary license is $40 per person per year. [2],[3]
This is an advance that deserves careful reporting. We need to distinguish what $40 buys from the regulatory step that “tentative approval” represents.
1 | What changes with treatment every six months?
Lenacapavir is used for pre-exposure prophylaxis, or PrEP: medication that protects people who do not have HIV but are at risk of acquiring it. Its antiviral effect comes from interfering with functions associated with the HIV capsid. Protection depends on maintaining an effective concentration in the body, so dosing must continue according to the prescribed schedule. [4]
The key evidence supporting prevention comes from two phase 3 studies, PURPOSE 1 and PURPOSE 2. In their initially published primary analyses, PURPOSE 1 enrolled adolescent girls and young women in South Africa and Uganda and observed no new HIV infections among 2,134 participants in the lenacapavir group. PURPOSE 2 enrolled men and participants of diverse gender identities and observed 2 infections among 2,179 participants in the lenacapavir group in its primary analysis. [5],[6]
These findings support a strong preventive effect. They also remind us that zero infections in a study applies to a defined population and follow-up period. Infections still occurred in another study, so the results do not mean that every user receives 100% protection.
A long-acting option also reduces the burden of managing medication every day. For people who find sustained daily pill-taking difficult, dosing every six months may be a better fit. Different people need different preventive options. Oral medicines, other long-acting products, and measures such as condoms all retain their place. [1]
2 | What exactly does “tentative approval” mean?
The Chinese word used for “tentative” may suggest that review of the evidence is unfinished. The FDA’s use of tentative approval for this category of HIV medicines has a specific meaning.
The FDA explains that these products must still meet its standards for safety, efficacy, and manufacturing quality. Because patents or exclusivity still protect the U.S. market, tentative approval does not itself permit U.S. sales. Qualifying products can, however, be procured for relevant programs, including the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). [7]
This step therefore provides an important basis for international procurement and subsequent access. It does not replace each country’s regulatory decisions, nor does it mean that all 120 countries already have stock.
A more accurate reading of the news is that a low-price generic has passed a key regulatory step. Procurement, local authorization, and actual supply must now follow.
3 | What does $40 a year cover?
First, the $40 price was not newly negotiated on this occasion. An agreement announced by Unitaid, CHAI, Wits RHI, and Dr. Reddy’s in September 2025 had already set it out. The new development in November 2026 is tentative FDA approval of the first generic injectable version. [2],[3]
Second, $40 is the annual price of the injectable drug. Under that same agreement announced in 2025, the oral initiation course needed when starting prevention is priced separately, at no more than $17. Testing, injection services, and follow-up also require resources. The $40 figure cannot be treated as the full cost of providing someone with a year of prevention services. [3]
Dosing frequency also needs precise wording. The originator product’s prescribing information requires oral medication at initiation, followed by continued dosing every six months. Each complete injectable dose requires two subcutaneous injections. “Dosing every six months” is therefore more accurate than “two shots a year.” [4]
Finally, the price has geographic and contractual boundaries. It applies to supply arrangements in the licensed territories. China is not on Gilead’s published list of 120 countries. The agreement does not mean that individuals in China or the United States can buy the drug for $40 a year. [8]
Explaining those boundaries makes the price’s real significance clearer: public-health programs in the relevant countries have an opportunity to expand prevention at a more affordable drug cost. Whether an individual receives it free, or how much they pay, depends on local policies and program arrangements.
4 | How was this path prepared in advance?
Looking only at an approval announcement misses the work that preceded it.
| October 2024 | Gilead granted non-exclusive, royalty-free voluntary licenses to six generic manufacturers, covering 120 specified countries. [9] |
| June 2025 | The originator lenacapavir product received U.S. FDA approval for HIV pre-exposure prophylaxis. [10] |
| September 2025 | Partners announced the $40 annual injectable-drug price agreement and provided development and regulatory-filing support. [3] |
| November 2026 | Dr. Reddy’s generic version received tentative FDA approval. [2] |
Preparations for generic manufacturing and subsequent supply therefore began before the originator medicine was approved for prevention. The originator company provided licenses, generic manufacturers undertook development and production, and global-health organizations supplied financial, technical, and regulatory support to help move the promise of low-price supply forward. [3],[9]
This also shows how access can be considered earlier in drug development. Discussing in advance who will manufacture a medicine, where it will be sold, how applications will be submitted, and at what price it will be supplied may shorten the wait later.
Voluntary licensing nevertheless retains geographic boundaries. Progress in covered territories deserves recognition, while access for people outside the license’s scope still requires discussion. [3],[8]
5 | What else is needed once the drug reaches a clinic?
Long-acting medicines reduce the frequency of daily pill-taking but require new arrangements in health services. Users must be able to return for doses on schedule. Health workers must perform testing, assessment, and proper injections. Supply must also be sustained.
HIV testing is a matter of medication safety. The prescribing information requires testing for HIV before starting and before every subsequent injection. If an infection is present but unrecognized, continuing this drug alone may increase the risk of resistance. Once infection is confirmed, the person needs to move to a complete HIV-treatment regimen. [4]
Injection-site reactions also need to be explained to users. In PURPOSE 2, approximately 1.2% of participants in the lenacapavir group discontinued the trial regimen because of injection-site reactions. A long-acting option can ease one burden while introducing another inconvenience that needs to be weighed. [6]
In its 2025 recommendations, the World Health Organization added long-acting lenacapavir as a preventive option and proposed expanding access through appropriately simplified testing and community services. Reliable testing, convenient services, and respect for privacy are practical tasks of implementation. [1]
They affect whether someone is willing to start and whether, six months later, they are willing and able to return. Knowing only how much drug sits in a warehouse cannot tell us whether prevention is actually happening.
6 | Which results should we watch next?
According to the joint November 2 announcement, the first generic products are expected to reach some countries before the end of 2026, with broader supply expected during 2027. These remain supply projections. Actual arrivals and coverage require subsequent verification. [2]
The next questions are which places actually receive the drug, whether procurement funding can be sustained, how many people start using it, and how many receive subsequent doses. Over a longer period, do new infections fall, and are people previously unable to access prevention services being reached?
These questions connect efficacy in clinical trials with real public-health gains.
The $40 annual price for the injectable drug, together with the first generic passing a key regulatory step, provides more concrete conditions for expanded prevention. How many lives those conditions change must be answered through subsequent supply, services, and real-world outcomes.
A new drug’s value is discovered in laboratories and clinical trials. It is also gradually realized when people who need it can keep using it.
Information current through November 3, 2026. Pricing, supply, and access arrangements may change with later disclosures.
Main sources
[5] Bekker et al., NEJM, 2024. PURPOSE 1 study.
[6] Kelley et al., NEJM, 2025; published online in 2024. PURPOSE 2 study.
[7] FDA. Standards for tentative approval of HIV medicines and PEPFAR procurement.
[9] Gilead, October 2, 2024. Voluntary-licensing announcement involving six generic manufacturers.
[10] CDC, MMWR, September 18, 2025. Evidence and recommendations for lenacapavir in HIV prevention.
Beyond the conclusion, there are still questions worth asking.
Medicine · Science · Ideas and reading
Follow Before the Conclusion as we stay curious and think independently together.